GSK Pharma re-enters oncology market

GlaxoSmithKline Pharma is re-entering the oncology market with the introduction of two advanced precision therapies for gynaecological cancer. The move signals GSK’s renewed focus on building a foothold in India’s cancer therapy, and widening its innovative portfolio .Nearly a decade ago, the company had exited the global oncology market after divesting much of its cancer portfolio to Novartis.Bhushan Akshikar, managing director, GSK Pharma said: “The launch of Jemperli and Zejula marks a pivotal moment for GSK in India, as we foray into oncology with a strong focus on innovation-led, high-impact therapies. These therapies address a critical unmet need in gynaecological cancers in India and represent meaningful progress in women’s cancer care.

With this launch, we are strengthening our long-term commitment to build the specialty medicine portfolio in India.

”The company will introduce the therapies Jemperli and Zejula, through a tiered pricing structure, he added.In India, where GSK is largely recognised for its strength in anti-infectives, respiratory medicines, pain management, and vaccines, the launch represents a notable shift in strategy.

Both Jemperli and Zejula are competitively priced and are in line with other immuno-oncology therapies in the market.Additionally, GSK is participating in oncology clinical trials in India to explore the potential of dostarlimab in treating other cancers, such as non-small cell lung, head and neck, and colorectal.